Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Myokardia Inc Cm ST (MYOK)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
MyoKardia to Present at 36th Annual J.P. Morgan Healthcare Conference

MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that Tassos Gianakakos,...

JPM : 112.27 (-0.36%)
MYOK : 52.00 (-1.70%)
Preclinical Studies with MyoKardia's Mavacamten Demonstrate Evidence of Reduced Contractility and Improved Left Ventricular Compliance

MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, presented data that further elucidates...

MYOK : 52.00 (-1.70%)
MyoKardia Presents Data from Study of Machine Learning Algorithm Intended to Identify Obstructive Hypertrophic Cardiomyopathy Using a Wearable Biosensor

MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, presented results from testing...

MYOK : 52.00 (-1.70%)
MyoKardia Reports Third Quarter 2017 Financial Results and Operational Progress

Received FDA Feedback for Mavacamten Registration Program in Symptomatic, Obstructive Hypertrophic Cardiomyopathy

MYOK : 52.00 (-1.70%)
MyoKardia Announces Presentations at 2017 American Heart Association Scientific Sessions

MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that company...

MYOK : 52.00 (-1.70%)
MyoKardia to Present at Two Upcoming Investor Conferences in November

MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced participation...

MYOK : 52.00 (-1.70%)
MyoKardia to Announce Third Quarter 2017 Financial Results on Thursday, November 2, 2017

MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that it will report...

MYOK : 52.00 (-1.70%)
Stock Performance Review on Biotech Industry -- MyoKardia, Nabriva Therapeutics, Puma Biotechnology, and PDL BioPharma

If you want a Stock Review on MYOK, NBRV, PBYI, or PDLI then come over to http://dailystocktracker.com/register/ and sign up for your free customized report. On Wednesday, the NASDAQ Composite ended the...

PDLI : 2.79 (-1.76%)
PBYI : 90.85 (-8.46%)
MYOK : 52.00 (-1.70%)
NBRV : 6.00 (-2.91%)
Best Sector ETF of Q3 and its Top-Performing Stocks

Inside the top performing stocks of top U.S.-focused ETF of Q3.

SGMO : 17.30 (-5.46%)
BBC : 29.85 (-3.55%)
DVAX : 14.65 (-6.98%)
KITE : 179.99 (+0.11%)
MYOK : 52.00 (-1.70%)
INSM : 29.57 (-6.60%)
Best Sector ETF of Q3 and its Top-Performing Stocks

Inside the top performing stocks of top U.S.-focused ETF of Q3.

SGMO : 17.30 (-5.46%)
BBC : 29.85 (-3.55%)
DVAX : 14.65 (-6.98%)
KITE : 179.99 (+0.11%)
MYOK : 52.00 (-1.70%)
INSM : 29.57 (-6.60%)
MyoKardia Provides Update on MYK-491 Clinical Progress

Single Ascending Dose Trial in Healthy Volunteers Continues Enrollment in Order to Refine Exposure-Activity-Relationship; Topline Data Expected by Early 2018

MYOK : 52.00 (-1.70%)
MyoKardia Presents Additional Positive Data from Phase 2 PIONEER-HCM Study of Mavacamten (Formerly MYK-461) at the Heart Failure Society of America's 21st Annual Scientific Meeting

MyoKardia, Inc. (Nasdaq:MYOK) ("MyoKardia" or the "Company"), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases,...

MYOK : 52.00 (-1.70%)
MyoKardia to Present at Two Upcoming Investor Conferences in September

MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced its participation...

WFC : 62.50 (-0.08%)
MYOK : 52.00 (-1.70%)
MyoKardia (MYOK) Looks Good: Stock Adds 6.32% in Session

MyoKardia, Inc.(MYOK) was a big mover last session, as the company saw its shares rise over 6% on the day.

MYOK : 52.00 (-1.70%)
MyoKardia Announces Closing of Public Offering of Common Stock Including Full Exercise of Option to Purchase Additional Shares

MyoKardia, Inc. (Nasdaq:MYOK) ("MyoKardia"), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced...

JPM : 112.27 (-0.36%)
MYOK : 52.00 (-1.70%)
Latest R&D Success, FDA Approvals and Significant Advances in Clinical Trials Boosting Biotech Sector

Biotech stocks have had an impressive run so far in 2017 with the NASDAQ Biotechnology Index (NBI) increasing over 19% year-to-date (YTD). Headlines in the active biotech sector include significant progress...

ESPR : 71.91 (-1.84%)
CLRB : 1.17 (-2.50%)
FGEN : 47.80 (-3.43%)
MYOK : 52.00 (-1.70%)
MBRX : 1.81 (-3.21%)
MyoKardia Announces Pricing of Public Offering of Common Stock

MyoKardia, Inc. (Nasdaq:MYOK) ("MyoKardia"), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced...

MYOK : 52.00 (-1.70%)
MyoKardia Announces Proposed Public Offering of Common Stock

MyoKardia, Inc. (Nasdaq:MYOK) ("MyoKardia" or the "Company"), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases,...

MYOK : 52.00 (-1.70%)
MyoKardia Reports Positive Topline Results in Phase 2 PIONEER-HCM Study of Mavacamten (Formerly MYK-461) in Symptomatic, Obstructive Hypertrophic Cardiomyopathy

Phase 2 Study Met Primary and Key Secondary Endpoints

MYOK : 52.00 (-1.70%)
MyoKardia to Announce Second Quarter 2017 Financial Results and Host Conference Call on Monday, August 7, 2017

MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that it will report...

MYOK : 52.00 (-1.70%)

Van Meerten Stock Picks

My 5 Favorite Mid Cap Stocks
This morning I wanted to find 5 Mid Cap stocks that had great returns over the past year and still seem to have some juice left.
KBH -1.63 , IPGP +2.02 , FSLR -2.19 , NVR -17.23 , SGMS +0.25
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

Barchart Morning Call

OVERNIGHT MARKETS AND NEWS Mar E-mini S&Ps ( ESH18 +0.39%) are up +0.41% at a fresh record nearest-futures high as growth optimism fuels gains in global equity markets. Gains in technology stocks are leading the overall market higher as... Read More

Chart of the Day

Chart of the Day

Audentes Therapeutcs (BOLD) is rhe Barchart Chart of the Day.  The biomedical company has a Trend Spotter buy signal, a Weighted Alpha of 174.58+ and gained 111.74% in the last year.
Read More

Brugler Ag Report

Today's Commentary

Corn futures bounced back from Friday’s bearish USDA reports to close Tuesday with gains of 2 cents in most nearby contracts. The weekly Export Inspections report indicated just 584,389 MT of corn was shipped during the week of Jan 11. That is ...
Read More

Alan Brugler writes this daily agricultural markets overview with opening, midday and closing comments directed at the gain and meat Ag markets.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.